Boston Scientific has resumed enrolment for its AVANT GUARD clinical trial, after it was paused in October 2024to “assess a few unanticipated observations”. The trial – which tests Boston ...

The AVANT GUARD trial investigates the safety and efficacy of pulsed field ablation (PFA) as a first-line treatment for persistent atrial fibrillation. Credit: Sundry Photography via Shutterstock.

Boston Scientific Corporation (NYSE:BSX) has announced the resumption of its AVANT GUARD clinical trial, which is focused on a new group of drug-naïve patients with persistent atrial fibrillation.

CEO Mike Mahoney said during the company's morning earnings call that Boston Scientific has "elected to temporarily pause" a trial of its Farapulse device in patients with atrial fibrillation who ...

The global spinal cord stimulators market is on a robust growth trajectory, poised to reach an impressive valuation of USD 5,441.4 million by 2033. Currently valued at USD 2,702.7 million in 2023, the ...

Boston Scientific Corporation (NYSE:BSX) has announced the resumption of its AVANT GUARD clinical trial, which is focused on a new group of drug-naïve patients with persistent atrial fibrillation. The ...

Late last month, Boston ... we can get the trial done successfully,” Stein said. Alongside the pause announcement on the company’s third-quarter earnings call, Boston Scientific also reported ...